New combo shows promise in Tough-to-Treat head and neck cancer
Disease control
Completed
This study tested whether adding the drug buparlisib to standard chemotherapy (paclitaxel) helps people with advanced head and neck cancer live longer. About 487 adults whose cancer had returned or spread and who had already tried other treatments took part. The goal was to see i…
Phase: PHASE3 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC